摘要
Managing Editor:Peng Lyu.Chemotherapy-induced thrombocytopenia(CIT)is a common complication that increases bleeding risks and necessitates chemotherapy dose reduction or discontinuation,which decreases therapeutic benefits and worsens the chances of survival.1 Current therapeutic options,such as platelet transfusion,administration of recombinant interleukin(IL)-11,and treatment with thrombopoietin receptor agonists,have potential drawbacks,including transfusion-related allergic reactions,fluid retention-induced heart disease,and the emergence of anti-thrombopoietin antibodies.
